TargetBeta
JAK3
Janus kinase 3 · also L-JAK, JAKL, LJAK, JAK3_HUMAN · Jak family tyrosine kinases
8 programs in company-led studies act on JAK3, from 7 companies: 4 in phase 3, 4 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (8 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| upadacitinibrule | AbbVie | phase 4 | 6424 running | JAK1, JAK2, TYK2 | ChEMBL |
| ruxolitinibrule | Incyte | phase 4 | 9518 running | JAK1, JAK2, TYK2 | ChEMBL |
| tofacitinibrule | Pfizer | phase 4 | 943 running | JAK1, JAK2, TYK2 | ChEMBL |
| filgotinib maleaterule | Eisai | phase 4 | 21 running | JAK1, JAK2, TYK2 | ChEMBL |
| ritlecitinibrule | Pfizer | phase 3 | 428 running | BMX, BTK, ITK, TEC, TXK | NCIt |
| jaktinibrule | Suzhou Zelgen Biopharmaceuticals | phase 3 | 318 running | FLT3, JAK1, JAK2 | the studies' text |
| filgotinibrule | Lakefront Biotherapeutics NV | phase 3 | 464 running | JAK1, JAK2, TYK2 | ChEMBL |
| delgocitinibrule | LEO Pharma | phase 3 | 212 running | JAK1, JAK2, TYK2 | ChEMBL |
Conditions their studies are in
- Arthritis, Rheumatoid, 5 programs
- Alopecia Areata, 4 programs
- Colitis, Ulcerative, 4 programs
- Dermatitis, Atopic, 4 programs
- Arthritis, Juvenile, 2 programs
- Arthritis, Psoriatic, 2 programs
- Crohn Disease, 2 programs
- Primary Myelofibrosis, 2 programs
- Psoriasis, 2 programs
- Vitiligo, 2 programs
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 2026upadacitinib · AbbVie · phase 4 · NCT06389136
- Dec 2026tofacitinib · Pfizer · phase 4 · NCT07843693
- Dec 2, 2026ritlecitinib · Pfizer · phase 3 · NCT07029711
- Dec 9, 2026ruxolitinib · Incyte · phase 4 · NCT07049575
- Feb 2027jaktinib · Suzhou Zelgen Biopharmaceuticals · phase 3 · NCT07565597
- Jun 2027filgotinib · Lakefront Biotherapeutics NV · phase 3 · NCT07554495
- Jun 4, 2027delgocitinib · LEO Pharma · phase 3 · NCT07013201
- Nov 30, 2027filgotinib maleate · Eisai · phase 4 · NCT06964113
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.